Sernova Biotherapeutics Inc SEOVF
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.21M | 1.35M | 1.21M | 1.14M | 1.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.52M | 1.68M | 1.53M | 1.73M | 2.55M |
| Operating Income | -1.52M | -1.68M | -1.53M | -1.73M | -2.55M |
| Income Before Tax | -1.84M | -2.35M | -1.74M | -1.62M | -2.95M |
| Income Tax Expenses | -32.20K | -- | -51.90K | -39.60K | 15.40K |
| Earnings from Continuing Operations | -1.81M | -2.35M | -1.68M | -1.58M | -2.97M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.81M | -2.35M | -1.68M | -1.58M | -2.97M |
| EBIT | -1.52M | -1.68M | -1.53M | -1.73M | -2.55M |
| EBITDA | -1.51M | -1.67M | -1.52M | -1.69M | -2.41M |
| EPS Basic | 0.00 | -0.01 | -0.01 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 377.64M | 351.12M | 336.40M | 328.71M | 328.48M |
| Average Diluted Shares Outstanding | 377.64M | 351.12M | 336.40M | 328.71M | 328.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |